Whalesbook
Strong Quarter Driven by Revenue Growth
Ajanta Pharma Ltd. finished fiscal year 2026 with a strong fourth quarter. Net profit increased 18.4% from the previous year to ₹266.7 crore. This boost came from a significant 21.5% jump in revenue, reaching ₹1,421.6 crore, up from ₹1,170.4 crore. For the full fiscal year 2026, revenue grew 17% to ₹5,453 crore. The company maintained a profit after tax margin of 19% throughout the year, showing consistent financial management.
Forex Loss Dents Reported Margins, Adjusted Figures Strong
Despite strong revenue and profit numbers, reported EBITDA for the quarter grew a more modest 12.2% to ₹333.4 crore. This led to a lower EBITDA margin of 23.5%, down from 25.4% a year ago. The main reason for this dip was a ₹42 crore foreign exchange loss. Excluding this forex impact, Ajanta Pharma's adjusted EBITDA climbed 26% year-on-year to ₹375 crore, with an adjusted margin of 26%. These adjusted figures better reflect the company's core operational strength.
For the full fiscal year 2026, reported EBITDA rose 11% to ₹1,395 crore, holding a 26% margin. The full-year forex loss totaled ₹103 crore. When adjusted for this, full-year EBITDA grew 18% to ₹1,498 crore, with a stronger margin of 27%. Ajanta Pharma also achieved a 33% return on capital employed and a 25% return on net worth for FY26.
Boosting R&D and Expanding Product Pipeline
Ajanta Pharma is investing more in research and development for future growth. R&D expenses in the fourth quarter increased to ₹70 crore from ₹53 crore the previous year. Full-year R&D spending went up to ₹252 crore from ₹161 crore. This spending accounts for 5% of revenue, in line with industry focus on innovation. Regarding regulations, Ajanta Pharma filed five Abbreviated New Drug Applications (ANDAs) in FY26 and received approvals for four. It also launched four new products, bringing its total commercialized ANDAs to 49. By the end of FY26, 19 ANDAs were awaiting US FDA approval, with six already receiving tentative approval.
Analyst Views and Market Valuation
As of May 5, 2026, Ajanta Pharma had a market capitalization of about ₹36,000 crore, placing it as a mid-cap company in the pharma sector. Its trailing twelve-month price-to-earnings (P/E) ratio was around 34.76, higher than its 10-year median P/E of 27.11, suggesting a premium valuation. Some analysts view this valuation as fair, with the stock trading slightly below its estimated value. Analysts generally have a positive outlook, with most recommending 'Buy' or 'Strong Buy'. The average 12-month price target is approximately ₹3,203, suggesting a potential upside of over 11% from its recent trading price of ₹2,910. High estimates reach ₹3,742, and low targets are around ₹2,605.
Key Risks: Regulatory Checks and Currency Volatility
Despite Ajanta Pharma's operational strength, some risks need attention. The company's Paithan facility received five observations from the USFDA. This could potentially lead to manufacturing or export delays if not resolved promptly. Also, ongoing foreign exchange volatility, as seen this quarter, can hide true profitability and make earnings less predictable, particularly for companies with large export sales. Compared to peers like Mankind Pharma, which has a lower P/E ratio, Ajanta Pharma's current valuation might seem high. While its R&D spending supports long-term growth, these investments must prove effective to justify the valuation amid rising competition and possible price pressures in the US, where sector growth is slowing.
Outlook: Pharma Sector Growth and Ajanta's Position
Ajanta Pharma is part of the Indian pharmaceutical sector, which is poised for continued growth, mainly from its strong domestic market and varied export demand. Forecasts suggest overall sector revenue growth of 7-9% for FY26, with the domestic market expected to grow 8-10%. Ajanta Pharma's R&D investments and its regulatory pipeline position it well to benefit from these opportunities. However, managing potential US FDA scrutiny and foreign exchange changes will be key to its long-term success.